Why is it necessary to screen antibodies for both ELISA and LFIA?

Antibodies that perform well in ELISA may not always be optimal for LFIA, and vice - versa. ELISA is a plate - based assay with multiple wash steps, while LFIA is a rapid, flow - through assay. Screening for both ensures that the selected antibodies possess the necessary characteristics, such as appropriate affinity and kinetics, to function effectively in both assay formats, guaranteeing their versatility.

What are the key factors that make an antibody suitable for LFIA?

For LFIA, antibodies need to exhibit high affinity and fast binding kinetics. This is because the interaction between the antibody and antigen occurs rapidly on the LFIA strip. Additionally, antibodies should have high specificity to minimize cross - reactivity and ensure accurate results in the rapid test format.

What types of antibodies do you produce, and what are the advantages of each?

We primarily produce monoclonal antibodies. Monoclonal antibodies offer high specificity, recognizing a single epitope on the antigen. This specificity leads to more precise and reproducible results in both ELISA and LFIA. While we focus on monoclonal antibodies, we can also generate polyclonal antibodies if needed for a client's specific application.

How do you ensure the quality and specificity of the antibodies you produce?

We follow strong quality control procedures at each phase of the antibody development process. This includes careful immunogen design, optimized immunization protocols, and extensive screening using both ELISA and LFIA. We also perform antibody characterization assays, such as Western blotting and other binding assays, to verify the specificity and affinity of the antibodies.

What sample types are suitable for your LFIA validation process?

We can work with a variety of sample types for LFIA validation, depending on the specific application. Common sample types include serum, plasma, and purified antigen solutions. We can also adapt our protocols to accommodate other sample types, but additional optimization and validation may be required. We collaborate closely with our clients to ensure that the validation process accurately reflects their intended LFIA application.

What formats of ELISA can you support?

We have extensive experience with various ELISA formats, including direct, indirect, competitive, and sandwich ELISA. We can tailor our antibody development and screening process to ensure that the generated antibodies are optimized for the specific ELISA format that our clients intend to use. Sandwich ELISA is a very common format, and we have significant expertise in generating antibody pairs for this assay type.

Precision Antibody Replication Services

Overview Workflow Service Published Data Features FAQ

The precision antibody replication services at Creative Biolabs provide clients with accurate and reliable reproduction of existing antibodies. We leverage advanced hybridoma technology and epitope determination techniques to deliver customized solutions. With our expertise, customers can expect highly specific antibodies, scalable production, and comprehensive support throughout the entire process, ensuring consistent and dependable results.

Overview of Precision Antibody Replication

Precise antibody replication is predicated on the accurate reproduction of antibodies exhibiting exquisite specificity for defined epitopes, the unique antigenic determinants that elicit robust immune responses and critically dictate the molecular mechanisms of antibody binding. These epitopes, which can present as linear amino acid sequences or complex three-dimensional conformational structures, represent the precise molecular interaction sites for antibody paratopes. The faithful replication of such highly specific antibodies is critical for effective and targeted immunity against diverse pathogens and holds fundamental importance in vaccine development, enabling the generation of antibodies that precisely neutralize specific disease agents with minimal off-target cross-reactivity. Moreover, this capability is essential for advanced diagnostics and targeted therapeutics, facilitating the development of tailored antibodies with significantly enhanced efficacy and a notable reduction in potential off-target side effects through the precise molecular recognition of specific antigenic determinants.

Fig.1 Antigen epitope recognition by antibodies paratopes. (Bukhari, et al., 2022) Fig.1 Antigen recognition by antibodies: interactions between epitopes and paratopes.^{1, 3}

Workflow of Hybridoma-based Precision Antibody Replication

Our approach combines classical hybridoma technology with state-of-the-art techniques to guarantee the generation of antibodies that precisely match the specificity and affinity of the original antibody. We begin with a thorough analysis of the target epitope and proceed through a series of optimized steps to deliver high-quality, replicated antibodies.

Fig.2 The process of precision antibody replication. (Creative Biolabs Original) Fig.2 Precision antibody replication service workflow.

Target Epitope Determination

The process commences with the identification of the precise region on the antigen that the antibody recognizes, known as the epitope. Accurate epitope determination is paramount for successful antibody replication, as it ensures that the replicated antibodies will bind to the same target with the same specificity. We employ techniques such as X-ray crystallography, peptide mapping, and bioinformatics analysis to map the epitope.

Immunogen Design

Following epitope determination, a carefully designed immunogen is synthesized. This immunogen, which mimics the target epitope, is crucial for eliciting an immune response that generates antibodies with the desired specificity. Our team of experts utilizes advanced molecular biology techniques to create immunogens that accurately represent the target epitope, ensuring optimal antibody generation.

Immunization

Subsequently, the designed immunogen is used to immunize host animals, typically mice. This immunization process triggers the animals' immune systems to create B cells that generate antibodies specific to the target epitope. We employ refined immunization protocols to enhance the immune response and maximize the yield of high-affinity antibody-producing B cells.

Hybridoma Preparation and Antibody Production

B cells from the immunized animals are then harvested and fused with myeloma cells to create hybridomas. These hybridoma cells combine the antibody-producing ability of B cells with the immortality of myeloma cells, enabling continuous and stable antibody production. Our optimized fusion and selection methods ensure the generation of robust hybridoma cell lines. Finally, the selected hybridoma clones are cultured to produce the desired antibodies.

Epitope Determination and Validation

The produced antibodies then undergo rigorous testing, including epitope validation assays, to confirm their specificity and affinity for the original target epitope. This validation step guarantees that the replicated antibodies adhere to the highest quality standards and function as intended in subsequent applications.

Precision Antibody Replication Service

For commercial monoclonal antibodies or reported antibody candidates with epitope information, Creative Biolabs provides precise antibody replication services. Through our professional epitope determination technology and mature antibody production solutions, you can obtain satisfactory customized antibodies. Immunogen design service is one of our core technical services. We offer complementary protein expression or peptide design services to generate custom antibodies with better performance.

Published Data

Phage display and antibody production. Fig.3 Different types of phage display libraries.^{2, 3}

In this article, researchers offer a comprehensive overview of the advancement of phage display libraries as potent tools for therapeutic antibody discovery. They meticulously outline the complex procedures involved in antibody development leveraging phage display technology. The process initiates with the establishment of a diverse library, which involves integrating genetic sequences encoding antibody fragments or peptides into the genomes of bacteriophages. This integration leads to the exhibition of numerous unique antibody candidates on the phage surface, constituting the core of the library. The extensive diversity within this library sets the stage for the subsequent search and identification of potential binding partners.

Features of Our Service

We ensure replicated antibodies match the high specificity of the original antibody, crucial for applications like therapeutic interventions and diagnostic assays.
Our customized antibodies target specific epitopes, enabling highly effective and selective tools, with flexibility in antibody format, purification, and labeling.
Cutting-edge techniques, including X-ray crystallography, peptide mapping, and advanced bioinformatics, accurately identify antigenic epitopes, ensuring replicated antibodies bind to the intended target.
This precision facilitates targeted therapy development, improves diagnostic accuracy, and enhances vaccine efficacy through epitope-focused design.
We provide comprehensive support for your research and development needs, from consultation to delivery, ensuring project success.

FAQ

Q: What types of antibodies can you replicate?
Our service is designed to replicate monoclonal antibodies (mAbs) produced using hybridoma technology. We specialize in replicating antibodies with known epitope information to ensure the highest degree of accuracy.
Q: How do you ensure the specificity of the replicated antibodies?
We employ rigorous epitope determination and validation techniques, such as ELISA, Surface Plasmon Resonance (SPR), and flow cytometry, to confirm that the replicated antibodies bind to the same target epitope as the original antibody. These assays guarantee the specificity and affinity of the final product.
Q: Can you produce antibodies in different formats (e.g., IgG, Fab fragments)?
Yes, we offer flexibility in antibody formats. We can produce replicated antibodies in various formats, including full-length IgG, Fab fragments, and other antibody fragments, to meet your specific application requirements.
Q: What level of purity can I expect from the replicated antibodies?
We utilize advanced purification techniques, including affinity chromatography, to ensure that the replicated antibodies are of the highest purity. The final purity level is typically greater than 95%, suitable for most research and diagnostic applications.
Q: How do you maintain the confidentiality of my antibody information?
We recognize the value of confidentiality and have robust protocols to safeguard your intellectual property. We are happy to sign confidentiality agreements (CDAs) and ensure that all project-related information is handled with the utmost care and security.
Q: What factors influence the success of antibody replication?
The success of antibody replication depends on several factors, including the quality of the original antibody, the availability of epitope information, and the complexity of the epitope itself. Our expertise in epitope determination and hybridoma technology helps to maximize the success rate.
Q: What kind of assistance do you offer after the antibodies are delivered?
We offer comprehensive post-delivery support, including technical assistance, troubleshooting, and additional antibody production if needed. Our team of specialists is here to answer any questions and ensure your complete satisfaction with our services.
Q: Do you offer antibody labeling or conjugation services?
Yes, we provide antibody labeling and conjugation services. We can conjugate the replicated antibodies with various labels, such as fluorescent dyes, enzymes, or other molecules, to facilitate their use in specific applications like flow cytometry, ELISA, or immunohistochemistry.

To solve the recurrence crisis of antibodies and improve the speed of antibody development, Creative Biolabs provides innovative precision antibody replication services for worldwide clients. If you are interested in learning more about our immunogen design services, please contact us directly. One of our experts will contact you shortly.

References

Bukhari, Syed Nisar Hussain, et al. "Machine learning techniques for the prediction of B-cell and T-cell epitopes as potential vaccine targets with a specific focus on SARS-CoV-2 pathogen: A review." Pathogens 11.2 (2022): 146.
Zhang, Tiantian, and Zhe Wang. "Monoclonal Antibody Development for Cancer Treatment Using the Phage Display Library Platform." Biologics 4.1 (2024): 55-74.
Distributed under Open Access license CC BY 4.0, without modification.

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

	USA: Europe: Germany:
	Call us at: USA: UK: Germany:
	Fax:
	Email: